Skip to main content
Premium Trial:

Request an Annual Quote

Indiana Proteomics Consortium Changes Name to Inproteo

NEW YORK, July 7 - The Indiana Proteomics Consortium today announced that it has officially changed its name to Inproteo - a name chosen to emphasize the commercial goals of the effort, consortium officials said today.


"The new name suggests where we are and what we do," said John Hurrell, Inproteo's president, in a statement. "It also implies that we are a commercial venture - our research is meant to have an economic impact."


The consortium was founded in 2002 as a partnership between Indiana University, Purdue University, and Eli Lilly. Research conducted under the auspices of Inproteo will be commercialized through the creation of new companies, joint ventures, or licensing partnerships.


Inproteo said it has filed 19 patents within its first year.


Additional information on Inproteo is available here.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.